搜索  
   
Homepage  |  BOCI View  |  Institutional Investor  |  Individual Investor  |  About BOCI  |  Career
     
News Center
Research Reports
Case Study
BOCI participated in the listing of CR Pharma on the Main Board of HKSE
 

China Resources Pharmaceutical Group Limited (“CR Pharma”) was listed on the Main Board of Hong Kong Stock Exchange on October 28 after the completion of the Global Offering. BOCI acted as a Joint Bookrunner in this IPO. CR Pharma has raised HK$14.0bn (US$1.8bn) from its Hong Kong IPO after selling 1.54 billion shares at HK$9.10 per share. This IPO has attracted 8 cornerstone investors. There is a greenshoe option of 234.5 million shares.

 

 

Back

©BOCI Copyright 2011